Survival and Tolerability of Liver Radioembolization: a Comparison of Elderly and Younger Patients with Metastatic Colorectal Cancer

Overview

Journal HPB (Oxford)

Publisher Elsevier

Specialty Gastroenterology

Date 2014 Aug 16

PMID 25123597

Citations 9

Authors

Samer Tohme

Daniel Sukato

Gary W Nace

Albert Zajko

Nikhil Amesur

Philip Orons

Didier Chalhoub

James W Marsh

David A Geller

Allan Tsung

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the outcomes among elderly (≥70 years) and younger patients (<70 years) with liver-dominant metastatic colorectal cancer (mCRC) who received radioembolization (RE) as salvage therapy.

Methods: A retrospective review of 107 consecutive patients with unresectable mCRC treated with RE after failing first- and second-line chemotherapy.

Results: From 2002 to 2012, 44 elderly and 63 younger (<70 years) patients received RE. Patients had similar previous extensive chemotherapy and liver-directed interventions. Using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria, either a stable or a partial radiographical response was seen in 65.8% of the younger compared with 76.5% of the elderly patients. RE was equally well tolerated in both groups and common procedure-related adverse events were predominantly grade 1-2 and of short duration. No significant difference was found with regard to overall median survival between younger [8.4 months; 95% confidence interval (CI) = 6.2-10.6] or elderly patients (8.2 months; 95% CI = 5.9-10.5, P = 0.667). The presence of extrahepatic disease at the time of RE was associated with a significantly worse median survival in both groups.

Conclusion: Radioembolization appears to be as well tolerated and effective for the elderly as it is for younger patients with mCRC. Age alone should not be a discriminating factor for the use of radioembolization in the management of mCRC patients.

Citing Articles

Efficacy and Safety of Transarterial Radioembolization in Elderly Patients with Hepatocellular Carcinoma: A Single-Center Experience.

Karaogullarindan U, Gumurdulu Y, Uskudar O, Odabas E, Guler H, Geckalan C Turk J Gastroenterol. 2024; 35(3):204-211.

PMID: 39128104 PMC: 11059000. DOI: 10.5152/tjg.2024.23155.

Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases.

Khin N, De Silva M, Clarke S, Pavlakis N, Rogan C, Ho-Shon K Ann Surg Oncol. 2022; 29(6):3387-3389.

PMID: 35147822 PMC: 9072514. DOI: 10.1245/s10434-022-11348-z.

Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies.

Correa E, Lindsay T, Dotan E Drugs Aging. 2021; 38(8):639-654.

PMID: 34143421 PMC: 9951235. DOI: 10.1007/s40266-021-00869-z.

Mode of progression after radioembolization in patients with colorectal cancer liver metastases.

van Roekel C, Jongen J, Smits M, Elias S, Koopman M, Kranenburg O EJNMMI Res. 2020; 10(1):107.

PMID: 32960390 PMC: 7509032. DOI: 10.1186/s13550-020-00697-z.

Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.

Walter T, Hawkins N, Pollock R, Colaone F, Shergill S, Ross P J Cancer Res Clin Oncol. 2020; 146(10):2575-2587.

PMID: 32715436 PMC: 7467965. DOI: 10.1007/s00432-020-03315-6.

References

Chiappa A, Zbar A, Bertani E, Biella F, Audisio R, Staudacher C . Surgical outcomes for colorectal cancer patients including the elderly. Hepatogastroenterology. 2001; 48(38):440-4. View

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

Boyle P, Elena Leon M . Epidemiology of colorectal cancer. Br Med Bull. 2002; 64:1-25. DOI: 10.1093/bmb/64.1.1. View

Schiffmann L, Ozcan S, Schwarz F, Lange J, Prall F, Klar E . Colorectal cancer in the elderly: surgical treatment and long-term survival. Int J Colorectal Dis. 2008; 23(6):601-10. DOI: 10.1007/s00384-008-0457-5. View

Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J . Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol. 2011; 35(5):1066-73. DOI: 10.1007/s00270-011-0234-7. View

Jestin P, Nilsson J, Heurgren M, Pahlman L, Glimelius B, Gunnarsson U . Emergency surgery for colonic cancer in a defined population. Br J Surg. 2004; 92(1):94-100. DOI: 10.1002/bjs.4780. View

Nace G, Steel J, Amesur N, Zajko A, Nastasi B, Joyce J . Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol. 2012; 2011:571261. PMC: 3263679. DOI: 10.1155/2011/571261. View

Saxena A, Bester L, Shan L, Perera M, Gibbs P, Meteling B . A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol. 2013; 140(4):537-47. DOI: 10.1007/s00432-013-1564-4. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

10.

Riemsma R, Bala M, Wolff R, Kleijnen J . Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. Cochrane Database Syst Rev. 2012; (9):CD009498. DOI: 10.1002/14651858.CD009498.pub2. View

11.

Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A . Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008; 112(7):1538-46. DOI: 10.1002/cncr.23339. View

12.

Bester L, Meteling B, Pocock N, Pavlakis N, Chua T, Saxena A . Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol. 2011; 23(1):96-105. DOI: 10.1016/j.jvir.2011.09.028. View

13.

Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J . Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010; 28(23):3687-94. DOI: 10.1200/JCO.2010.28.5643. View

14.

Chua T, Bester L, Saxena A, Morris D . Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol. 2010; 137(5):865-73. DOI: 10.1007/s00432-010-0948-y. View

15.

Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355(9209):1041-7. DOI: 10.1016/s0140-6736(00)02034-1. View

16.

Tomlinson J, Jarnagin W, DeMatteo R, Fong Y, Kornprat P, Gonen M . Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007; 25(29):4575-80. DOI: 10.1200/JCO.2007.11.0833. View

17.

Salem R . Radioembolization with 90Y microspheres: technical considerations. J Vasc Interv Radiol. 2007; 18(11):1460-1. DOI: 10.1016/j.jvir.2007.07.031. View

18.

Sangro B, Inarrairaegui M, Bilbao J . Radioembolization for hepatocellular carcinoma. J Hepatol. 2011; 56(2):464-73. DOI: 10.1016/j.jhep.2011.07.012. View

19.

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2003; 22(2):229-37. DOI: 10.1200/JCO.2004.05.113. View

20.

Egenvall M, Schubert Samuelsson K, Klarin I, Lokk J, Sjovall A, Martling A . Management of colon cancer in the elderly: a population-based study. Colorectal Dis. 2014; 16(6):433-41. DOI: 10.1111/codi.12575. View